3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
49
Phase 1
20
Phase 3
18
Phase 1/2
13
Phase 4
2
Phase NA
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Carcinoma, Renal Cell
5
Neuroendocrine Tumors
3
Neoplasms
3
Tuberous Sclerosis
2
Kidney Neoplasms
2
Breast Neoplasms
2
Angiomyolipoma
2
Waldenstrom Macroglobulinemia
1
Skin Neoplasms
1
Skin Diseases
1
Pancreatic Neuroendocrine Tumors
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Lymphoma
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Large Cell
1
Carcinoma, Hepatocellular
1
Carcinoid Tumor
1
Breast Diseases
1
Interventions
Letrozole
20
Docetaxel
16
Cyclophosphamide
13
Zoledronic Acid
12
exemestane
11
Trastuzumab
11
Anastrozole
11
Paclitaxel
10
Tamoxifen
9
Capecitabine
9
Fulvestrant
8
Epirubicin
8
pegfilgrastim
7
pertuzumab
6
liposomal doxorubicin
6
abemaciclib
6
Saline Solution
6
palbociclib
5
Sodium Chloride
5
Dexmedetomidine
5
Carboplatin
5
Bupivacaine
5
Bevacizumab
5
ribociclib
4
pegylated granulocyte colony-stimulating factor
4
eribulin
4
Tranexamic Acid
4
Standard of Care
4
Pamidronate
4
Filgrastim
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Breast Neoplasms
×
Everolimus
×
Clear all
NCT01743560
2019-07-18
4EVERUK
Novartis
Phase 4
Completed
52 enrolled
16 charts
NCT02248571
2017-11-13
IMPROVE
iOMEDICO AG
Phase 4
Completed
85 enrolled